If 2015 was a dream year for Wall Street’s top dealmakers, 2016 is starting to take a nightmarish turn. Some of the mega transactions that had champagne corks popping in boardrooms are running into antitrust problems and, in the case of pharmaceutical firm Pfizer Inc’s $160 billion takeover of rival Allergan, political opposition to a deal that envisaged the biggest drug company in the United States moving to Ireland to lower its taxes.
http://www.reuters.com/article/us-global-m-a-regulation-idUSKCN0X40CF
